JP2016535782A - 被験者の気道への酵素の投与のための組成物及び方法 - Google Patents

被験者の気道への酵素の投与のための組成物及び方法 Download PDF

Info

Publication number
JP2016535782A
JP2016535782A JP2016552448A JP2016552448A JP2016535782A JP 2016535782 A JP2016535782 A JP 2016535782A JP 2016552448 A JP2016552448 A JP 2016552448A JP 2016552448 A JP2016552448 A JP 2016552448A JP 2016535782 A JP2016535782 A JP 2016535782A
Authority
JP
Japan
Prior art keywords
composition
plasminogen activator
subject
solution
scupa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016552448A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535782A5 (enExample
Inventor
ロバート オー． ザ サード ウィリアムズ，
ロバート オー． ザ サード ウィリアムズ，
スティーブン イデル，
スティーブン イデル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53005414&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2016535782(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of JP2016535782A publication Critical patent/JP2016535782A/ja
Publication of JP2016535782A5 publication Critical patent/JP2016535782A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2016552448A 2013-11-04 2014-11-04 被験者の気道への酵素の投与のための組成物及び方法 Pending JP2016535782A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899739P 2013-11-04 2013-11-04
US61/899,739 2013-11-04
PCT/US2014/063784 WO2015066664A2 (en) 2013-11-04 2014-11-04 Compositions and methods for administration of an enzyme to a subject's airway

Publications (2)

Publication Number Publication Date
JP2016535782A true JP2016535782A (ja) 2016-11-17
JP2016535782A5 JP2016535782A5 (enExample) 2017-12-14

Family

ID=53005414

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016552448A Pending JP2016535782A (ja) 2013-11-04 2014-11-04 被験者の気道への酵素の投与のための組成物及び方法

Country Status (11)

Country Link
US (2) US20160279209A1 (enExample)
EP (1) EP3065705A4 (enExample)
JP (1) JP2016535782A (enExample)
KR (1) KR20160078986A (enExample)
CN (1) CN105764488A (enExample)
AU (1) AU2014341862A1 (enExample)
CA (1) CA2928759A1 (enExample)
CL (1) CL2016001062A1 (enExample)
MX (1) MX2016005720A (enExample)
PE (1) PE20160789A1 (enExample)
WO (1) WO2015066664A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230148263A (ko) 2013-03-15 2023-10-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
KR102958241B1 (ko) 2018-09-10 2026-04-30 레인 테라퓨틱스, 인크. Cav-1 단백질의 변형된 펩타이드 단편 및 섬유증의 치료에 있어서 이의 용도
WO2021180068A1 (zh) * 2020-03-09 2021-09-16 泰伦基国际有限公司 一种治疗2019新型冠状病毒引发疾病的方法和药物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006426A1 (en) * 1996-08-14 1998-02-19 Gram Joergen Brodersen Use of a plasminogen activator for the treatment of pulmonary disorders
WO2013029627A1 (en) * 2011-08-29 2013-03-07 Trifoilium Aps Compositions and methods for treating or preventing radiation- or chemotherapy-induced pulmonary dysfunction

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4790305A (en) * 1986-06-23 1988-12-13 The Johns Hopkins University Medication delivery system
EP0266032A1 (en) 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
US5302390A (en) 1987-07-01 1994-04-12 Beecham Group Plc Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment
US5531219A (en) 1994-11-04 1996-07-02 Alliance Pharmaceutical Corp. Use of liquid fluorocarbons to facilitate pulmonary drug delivery
US20030113271A1 (en) * 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
JP2005518274A (ja) * 2001-12-21 2005-06-23 エンバイロスクラブ テクノロジーズ コーポレイション マンガン酸化物の前処理および再生
WO2004062603A2 (en) * 2003-01-09 2004-07-29 Arizeke Pharmaceuticals Inc. Methods of treating lung diseases
US20050169908A1 (en) 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20060198940A1 (en) 2005-03-04 2006-09-07 Mcmorrow David Method of producing particles utilizing a vibrating mesh nebulizer for coating a medical appliance, a system for producing particles, and a medical appliance
WO2007008825A2 (en) 2005-07-11 2007-01-18 Emory University System and method for optimized delivery of an aerosol to the respiratory tract
ES2414957T3 (es) * 2005-12-21 2013-07-23 Solaeromed Inc. Tratamiento de enfermedades respiratorias
SI22865A (sl) 2008-09-25 2010-03-31 Univerza@V@Ljubljani Peptid uroaktivin kot aktivator encima urokinaze
AU2009319772A1 (en) * 2008-11-26 2010-06-03 Centocor Research & Development, Inc. Compositions and methods for regulating collagen and smooth muscle actin expression by SERPINE2
DE102009031274A1 (de) * 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006426A1 (en) * 1996-08-14 1998-02-19 Gram Joergen Brodersen Use of a plasminogen activator for the treatment of pulmonary disorders
WO2013029627A1 (en) * 2011-08-29 2013-03-07 Trifoilium Aps Compositions and methods for treating or preventing radiation- or chemotherapy-induced pulmonary dysfunction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF AEROSOL MEDICINE, 2000, VOL.13, NO.4, PP.325-333, JPN6018030413, ISSN: 0003989122 *
PHARMACY TODAY, NOVEMBER 2013, P.23, JPN6018030417, ISSN: 0003989123 *

Also Published As

Publication number Publication date
MX2016005720A (es) 2016-11-25
EP3065705A2 (en) 2016-09-14
WO2015066664A2 (en) 2015-05-07
PE20160789A1 (es) 2016-08-17
KR20160078986A (ko) 2016-07-05
CL2016001062A1 (es) 2017-01-13
US20160279209A1 (en) 2016-09-29
EP3065705A4 (en) 2017-10-18
US20190255157A1 (en) 2019-08-22
CN105764488A (zh) 2016-07-13
AU2014341862A1 (en) 2016-05-19
CA2928759A1 (en) 2015-05-07
US11033611B2 (en) 2021-06-15
WO2015066664A3 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
US20250387457A1 (en) Methods, Compounds and Compositions for Treatment of Influenza and Parainfluenza Patients
JP4990929B2 (ja) 肺臓内領域における活性成分のキャリヤーとしての半フッ素化アルカンの吸入及び点滴注入による使用
US20230212223A1 (en) Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis
US11033611B2 (en) Compositions and methods for administration of an enzyme to a subject's airway
JP2021080285A (ja) ポリペプチド治療及びその使用
WO2022009081A1 (en) Drug for use against the novel coronavirus disease, covid-19
JP2025011148A (ja) ウイルス性肺炎を治療する方法及び薬剤
EP3937966B1 (en) Compositions and methods for protecting type 2 alveolar epithelial cells (aec2)
US20180140547A1 (en) Compositions and methods for administration of an enzyme to a subject's airway
KR20220041744A (ko) 나파모스타트 또는 카모스타트를 포함하는 흡입용 제제
RU2496515C2 (ru) Введение в дыхательные пути активированного белка с при воспалительных состояниях, поражающих дыхательные пути
EP4149619A1 (en) Treatment of respiratory viral infections
US20260077052A1 (en) Methods For Reducing Or Preventing SARS-COV-2 Infection And Transmission
Gupta et al. Pulmonary delivery of human protein C and factor IX
WO2021188334A1 (en) Use of st266 to treat severe systemic inflammation and post-acute covid-19 syndrome
Samsudin Current issues and challenges in the use of aerosolized surfactant for respiratory distress syndrome in the newborns
Vanbever Optimization of dry powder aerosols for systemic drug delivery
HK40084754A (en) Method and drug for treating viral pneumonia
Abdalaziz et al. Formulation strategy for hydroxychloroquine as inhaler dosage from as a potential for COVID-19 treatment
WO2022140817A1 (en) Anti-viral proteases and methods of use
CA3204080A1 (en) Compositions, devices, and methods for treating respiratory disorders
HK40004532A (en) Methods, compounds and compositions for treating influenza and parainfluenza patients
Gupta et al. PULMONARY DELIVERY OF HUMAN PROTEIN

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180806

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190304